Andrew Mamoru Kawasaki

This inventor holds 31 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Oligonucleotide Chemistry. Top assignees: Isis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Center for Neurologic Study. Active years: 1996-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Mamoru Kawasaki. Retrieved from https://idiyas.com/inventor/andrew-mamoru-kawasaki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 3)

% Patents Active = 87.1

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.2

ph-index = 17

Forward Citations = 1,672(Granted Patents)

Location History:

Carlsbad, CA (US) (2000 - 2003)
Oceanside, CA (US) (1996 - 2006)
San Diego, CA (US) (2006 - 2022)

Company Filing History:

27 out of 1,035

Isis Pharmaceuticals, Inc.

patents

2 out of 218

Arena Pharmaceuticals, Inc.

patents

1 out of 2

Center for Neurologic Study

patents

4. 1 out of 1

Tonix Pharma Holdings Limited (Bermuda)

patent

Years Active: 1996-2022

Loading Chart...

Areas of Expertise:

Oligonucleotide Modifications

RNA Modulation

Heterocycle Compositions

Tricyclic Acid Derivatives

Gene Expression Detection

Aminooxy-Modified Compounds

2'-O-Modified Oligonucleotides

Antimicrobial Determination

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11535596 - Analogs of dextromethorphan with balanced receptor activities (2022-12-27),

2. 9403755 - Isometheptene isomer (2016-08-02),

3. 9108969 - Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders (2015-08-18),

4. 8415484 - Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders (2013-04-09),

5. 7138517 - Sugar modified oligonucleotides (2006-11-21),

6. 7119184 - Oligonucleotides having A-DNA form and B-DNA form conformational geometry (2006-10-10),

7. 6660466 - Di-nitrogen heterocycle compositions (2003-12-09),

8. 6639062 - Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom (2003-10-28),

9. 6624294 - Regioselective synthesis of 2′-O-modified nucleosides (2003-09-23),

10. 6610663 - Compositions and methods for modulating RNA (2003-08-26),

11. 6531584 - 2'modified oligonucleotides (2003-03-11),

12. 6403779 - Regioselective synthesis of 2′-O-modified nucleosides (2002-06-11),

13. 6358931 - Compositions and methods for modulating RNA (2002-03-19),

14. 6307040 - Sugar modified oligonucleotides that detect and modulate gene expression (2001-10-23),

15. 6277982 - Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates (2001-08-21),

Title: Andrew Mamoru Kawasaki: Innovator and Inventor

Introduction

Andrew Mamoru Kawasaki, based in Oceanside, CA, is a distinguished inventor known for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 31 patents, Kawasaki has developed innovative solutions aimed at improving pharmacological treatment options.

Latest Patents

Kawasaki's latest patents showcase his expertise and innovative thinking. One notable invention is the development of analogs of dextromethorphan, which exhibit balanced receptor activities. These substituted analogs demonstrate substantial binding affinity at both NMDA and sigma-1 receptors, while also being degraded by human liver enzymes at a slower rate compared to dextromethorphan. This advancement offers alternatives that can provide similar benefits without the need for a cytochrome P-450 enzyme inhibitor.

Another significant patent involves the synthesis and characterization of an Isometheptene isomer, particularly the (R)-enantiomer. This compound is praised for its selective activity as a centrally acting ligand for Imidazoline subtype 1 (I1) receptor sites. The invention promises an antihypertensive composition beneficial in treating migraine and neurogenic pain associated with abdominal distress, boasting lower side effects compared to its racemate form.

Career Highlights

Kawasaki has made a substantial impact in the pharmaceutical industry, having collaborated with leading companies such as Isis Pharmaceuticals and Arena Pharmaceuticals. His work has paved the way for advancements in drug development, particularly in the realm of pain management and hypertension.

Collaborations

In his professional journey, Andrew has collaborated with notable colleagues, including Phillip Dan Cook and Muthiah Manoharan. Their collective efforts have undoubtedly enriched the development of innovative therapeutics.

Conclusion

Andrew Mamoru Kawasaki stands as a prominent figure in the field of innovation, particularly in medicinal chemistry. His contributions through various patents highlight the ongoing potential for advancements in healthcare, offering hope and improved treatment options for patients in need.

Profile summary based on public USPTO records.